Skip to content
Preprint

Molexar: A Unified Multimodal Molecular Foundation Model for Drug Design

Jun 2026 · 0 citations · 70 references
Biology

TL;DR

The results establish Molexar as a practical unified foundation for computational chemistry and drug-design workflows and establish Molexar as a practical unified foundation for computational chemistry and drug-design workflows.

Abstract

Molecular generation is a central challenge in drug discovery, requiring models that explore vast chemical space while satisfying diverse design constraints. We present Molexar, a unified multimodal molecular foundation model built on Fragment-SELFIES, a robust, fragment-aware molecular language with validity-preserving decoding and explicit fragment structure. A pretrained autoregressive decoder learns the Fragment-SELFIES syntax and molecular distribution; supervised fine-tuning (SFT) then trains the same decoder on condition-molecule pairs spanning scalar molecular properties, pharmacophore fingerprints, protein sequences, and binding pockets, injecting each condition by in-place replacement of value-token embeddings so that all generation modes share one autoregressive path. Molexar achieves strong efficiency at a small parameter count while matching or exceeding larger models. The pretrained model reaches 100% validity and high drug-likeness in unconditional and fragment-constrained generation; the SFT model follows single- and multi-property instructions and remains competitive on target-conditioned generation on the CrossDocked2020 test set. On MolGenBench, Molexar further generates molecules with favorable safety and potency. These results establish Molexar as a practical unified foundation for computational chemistry and drug-design workflows.

View source

Similar papers

Open access Aug 2026

PockLigGPT: Pocket-Sequence-Conditioned Molecular Generation with GPTs and RL

PockLigGPT achieves competitive docking-oriented performance under a standardized evaluation protocol while maintaining chemical plausibility, favorable physicochemical profiles, and Lipinski-based drug-likeness.

Pablo Varas Pardo, Guillermo Marcos-Ayuso, Eugenia Ulzurrun et al. · 0 citations

Beyond Drug Discovery: The Nanotechnology Molecular Optimization (NMO) Benchmark

A new baseline method is developed identifying the critical components to solve the NMO tasks, including a novel representation for modeling structural constraints and a domain-agnostic pretraining strategy to eliminate pharmaceutical dataset bias.

Matthias Blaschke, Daniel Kienzle, Zsuzsanna Koczor-Benda et al. · 0 citations
Open access Jul 2026

Multimodal feature fusion for molecular property classification.

This study provides a large-scale empirical evaluation of multimodal feature fusion for molecular property classification by systematically integrating SMILES-based chemical language representations with fingerprint-based structural descriptors across 60 benchmark datasets.

Jing Liu, Li Xue, Yin Wang et al. · 0 citations
Jul 2026

Vilya-1: An all-atom foundation model for macrocycle structure prediction and design

Vilya-1 is introduced, a deep learning model that addresses two central challenges in macrocycle design: sampling biologically relevant conformations across arbitrary chemistries and predicting key developability properties such as membrane permeability.

Vilya Research Pascal Sturmfels, M. Salem, Naozumi Hiranuma et al. · 1 citation
Open access Jul 2026

StructureSAFE: A structure-aware chemical language model for unified hit identification and lead optimization

Structure-based generative models (SBGMs) hold great promises for accelerating drug discovery by enabling target-aware molecular design. However, existing approaches face fundamental challenges: three-dimensional graph-based models can explicitly incorporate protein structural information but often generate chemically...

Bo Yang, Ke Xu, Chijian Xiang et al. · 0 citations
Review Jul 2026

Beyond SBDD: Geometric Deep Learning in Polypharmacology and Multi-target Drug Design

This review elucidates the paradigm shift in drug discovery from serendipitous exploration to rational, structure-driven polypharmacological molecular engineering, thereby providing a clear, structured guide for navigating the complexities of next-generation therapeutics.

Tianming Han, Zhijie Pan, Wenchi Ge et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.